Lymphodepletion Strategies in CAR T-cell Therapy: Propensity-Matched Outcomes of Fludarabine/Cyclophosphamide Versus Bendamustine

Key Points

• Fludarabine/cyclophosphamide preparation led to statistically improved survival outcomes compared to bendamustine.
• The findings showed a 25% increase in overall survival rates for patients receiving CAR T-cell therapy with fludarabine/cyclophosphamide.
• Propensity matching analysis adjusted for baseline characteristics, ensuring a fair comparison between treatment groups.
• This study suggests potential benefits of specific lymphodepletion strategies in improving CAR T-cell therapy effectiveness.